Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPN14770 PK in Hepatic Impairment
NCT07018492Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zatolmilast in Fragile X syndrome (FXS) (4 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Area Under the Plasma Concentration Time Curve Extrapolated from Time 0 to Infinity, Maximum Observed Plasma Concentration and 1 more. Started Aug 2025; status: completed.
02
Drugs
zatolmilast
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT07018492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018492.